You have 9 free searches left this month | for more free features.

PS-341

Showing 1 - 25 of 746

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
  • +1 more
Jan 5, 2023

Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)

Active, not recruiting
  • Solid Tumor
  • Urethral Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 22, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Aug 5, 2022

Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)

Withdrawn
  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • nonmyeloablative allogeneic hematopoietic stem cell transplantation
  • +7 more
  • (no location specified)
Jan 4, 2023

Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)

Active, not recruiting
  • Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 10, 2023

Plasma Cell Myeloma Trial (Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • (no location specified)
Dec 22, 2022

Multiple Myeloma Based on Multi-omics

Enrolling by invitation
  • Multiple Myeloma
  • Bortezomib
  • Beijing, China
    Beijng Chao Yang Hospital
Apr 21, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)

Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Los Angeles, California
  • +1 more
Aug 19, 2022

Plasma Cell Myeloma, Renal Failure Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma
  • Renal Failure
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jun 13, 2022

AL Amyloidosis Trial in United States (Bortezomib, Cyclophosphamide, Dexamethasone)

Recruiting
  • AL Amyloidosis
  • Orange, California
  • +5 more
May 3, 2022

AL Amyloidosis Trial (procedure, drug, other)

Not yet recruiting
  • AL Amyloidosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +15 more
  • (no location specified)
Aug 28, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 30, 2021

Waldenstrom's Macroglobulinemia Trial in Boston (Everolimus, Rituximab, Bortezomib)

Terminated
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Apr 22, 2021

Myeloma Trial in Little Rock (Melphalan, Velcade, Thalidomide)

Active, not recruiting
  • Myeloma
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
Dec 1, 2021

Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,

Active, not recruiting
  • Autologous Hematopoietic Stem Cell Transplant Recipient
  • +4 more
  • Duarte, California
    City of Hope
Mar 17, 2022

Mantle Cell Lymphoma Trial in United States (Acalabrutinib, Bortezomib, Cyclophosphamide)

Recruiting
  • Mantle Cell Lymphoma
  • New Orleans, Louisiana
  • +5 more
Dec 13, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Multiple Myeloma Trial in Little Rock (Velcade, Melphalan, Thalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
Sep 7, 2021

Multiple Myeloma Trial in Chicago (Carfilzomib, Lenalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Chicago, Illinois
    University Of Chicago Medicine Comprehensive Cancer Center
Jun 7, 2021

Mantle Cell Lymphoma Trial in Houston (Bortezomib, Cyclophosphamide, Cytarabine)

Completed
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2022

Acute Lymphoblastic Leukemia Trial in Canada, United States (ITMHA, Dexamethasone, Mitoxantrone)

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • Los Angeles, California
  • +17 more
Jun 6, 2022

Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach

Completed
  • Adenocarcinoma of the Gastroesophageal Junction
  • +7 more
  • Bronx, New York
    Montefiore Medical Center
Jan 29, 2021

Myeloma Trial in Houston (Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan)

Completed
  • Myeloma
  • Trisenox (Arsenic Trioxide)
  • +3 more
  • Houston, Texas
    UT MD Anderson Cancer Center
Sep 1, 2020